Neurocrine Biosciences (NBIX) 10-Q 5 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	Apr. 29, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Trading Symbol	NBIX
Entity Registrant Name	NEUROCRINE BIOSCIENCES INC
Entity Central Index Key	914,475
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		86,656,029

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 115,301	$ 74,195
Short-term investments, available for sale	266,223	304,996
Receivables under collaboration agreements	15,083
Other current assets	4,377	4,883
Total current assets	400,984	384,074
Property and equipment, net	3,897	3,432
Long-term investments, available for sale	49,460	82,488
Restricted cash	4,991	4,791
Total assets	459,332	474,785
Current liabilities:
Accounts payable	2,122	2,561
Accrued liabilities	17,126	19,034
Current portion of cease-use liability	234	428
Current portion of deferred rent	345	269
Current portion of deferred gain on sale of real estate	3,449	3,423
Total current liabilities	23,276	25,715
Deferred gain on sale of real estate	10,019	10,898
Deferred revenue	10,231	10,231
Deferred rent	1,817	1,711
Cease-use liability	809	1,555
Other liabilities	221	221
Total liabilities	$ 46,373	$ 50,331
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 110,000,000 shares authorized; issued and outstanding shares were 86,573,076 as of March 31, 2016 and 86,262,594 as of December 31, 2015	$ 87	$ 86
Additional paid-in capital	1,347,558	1,340,579
Accumulated other comprehensive loss	(188)	(977)
Accumulated deficit	(934,498)	(915,234)
Total stockholders' equity	412,959	424,454
Total liabilities and stockholders' equity	$ 459,332	$ 474,785

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	110,000,000	110,000,000
Common stock, shares issued	86,573,076	86,262,594
Common stock, shares outstanding	86,573,076	86,262,594

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues:
License fees and milestones	$ 15,000	$ 19,769
Total revenues	15,000	19,769
Operating expenses:
Research and development	23,903	16,575
General and administrative	11,954	5,482
Total operating expenses	35,857	22,057
Loss from operations	(20,857)	(2,288)
Other income:
Gain on sale/disposal of assets	3	9
Deferred gain on real estate	853	830
Investment income, net	737	257
Total other income	1,593	1,096
Net loss	$ (19,264)	$ (1,192)
Net loss per common share:
Basic and diluted	$ (0.22)	$ (0.01)
Shares used in the calculation of net loss per common share:
Basic and diluted	86,497	80,349
Other comprehensive loss:
Net loss	$ (19,264)	$ (1,192)
Net unrealized gains on available-for-sale securities	789	98
Comprehensive loss	$ (18,475)	$ (1,094)

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (19,264)	$ (1,192)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	276	244
Gain on sale of assets	(856)	(839)
Deferred revenues	0	10,231
Deferred rent	(64)	(27)
Cease-use expense	(584)	0
Amortization of premiums on investments	1,397	1,011
Non-cash share-based compensation expense	6,918	3,600
Change in operating assets and liabilities:
Accounts receivable under collaboration agreements and other assets	(14,577)	(30,552)
Accounts payable and accrued liabilities	(2,347)	(546)
Cease-use liability	(110)	(113)
Net cash used in operating activities	(29,211)	(18,183)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of investments	(55,561)	(159,221)
Sales and maturities of investments	126,754	43,398
Deposits and restricted cash	(200)	0
Proceeds from sales of property and equipment	3	9
Purchases of property and equipment	(741)	(280)
Net cash provided by/ (used in) investing activities	70,255	(116,094)
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock	62	273,525
Net cash provided by financing activities	62	273,525
Net increase in cash and cash equivalents	41,106	139,248
Cash and cash equivalents at beginning of the period	74,195	31,014
Cash and cash equivalents at end of the period	$ 115,301	$ 170,262

ORGANIZATION AND SIGNIFICANT AC

ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES	1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Description of Business. Basis of Presentation These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The balance sheet at December 31, 2015 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. Impact of Recently Issued Accounting Standards In February 2016, the FASB issued Accounting Standards Update 2016-02 Leases. This update amends the current accounting guidance for lease transactions. Under the new guidance, a lessee will be required to recognize both assets and liabilities for any leases in excess of twelve months. Additionally, certain qualitative and quantitative disclosures will also be required in the financial statements. The Company is required to adopt this new guidance beginning in 2019 and early adoption is permitted. The Company is in the process of determining the effects the adoption of this update will have on its consolidated financial statements. In March 2016, the FASB issued Accounting Standards Update 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This update amends the current tax accounting rules for share-based compensation in an attempt to simplify the reporting of excess tax benefits and deficiencies related to equity compensation. Additionally, the FASB has provided an alternative for forfeiture estimations related to grants of equity awards. We are required to adopt this new guidance beginning in 2017 and early adoption is permitted. The Company is in the process of determining the effects the adoption of this update will have on its consolidated financial statements. Use of Estimates

REVENUE RECOGNITION AND SIGNIFI

REVENUE RECOGNITION AND SIGNIFICANT COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS	3 Months Ended
	Mar. 31, 2016
Text Block [Abstract]
REVENUE RECOGNITION AND SIGNIFICANT COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS	2. REVENUE RECOGNITION AND SIGNIFICANT COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS Revenue Recognition Policy. The Company recognizes revenue for the performance of services when each of the following four criteria is met: (i) persuasive evidence of an arrangement exists; (ii) services are rendered or products are delivered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured. Since 2011, the Company has followed the Accounting Standards Codification (ASC) for Revenue Recognition—Multiple-Element Arrangements, if applicable, to determine the recognition of revenue under license and collaboration agreements. The terms of these agreements generally contain multiple elements, or deliverables, which may include (i) licenses to the Company’s intellectual property, (ii) materials and technology, (iii) pharmaceutical supply, (iv) participation on joint development or joint steering committees, and (v) development services. The payments the Company receives under these arrangements typically include one or more of the following: up-front license fees; funding of research and/or development efforts; amounts due upon the achievement of specified milestones; manufacturing and royalties on future product sales. The ASC provides guidance relating to the separation of deliverables included in an arrangement into different units of accounting and the allocation of consideration to the units of accounting. The evaluation of multiple-element arrangements requires management to make judgments about (i) the identification of deliverables, (ii) whether such deliverables are separable from the other aspects of the contractual relationship, (iii) the estimated selling price of each deliverable, and (iv) the expected period of performance for each deliverable. To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances for each arrangement. The selling prices of deliverables under an arrangement may be derived using vendor specific objective evidence (VSOE), third-party evidence, or a best estimate of selling price (BESP), if VSOE or third-party evidence is not available. For most pharmaceutical licensing and collaboration agreements, BESP is utilized. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the agreement was sold on a standalone basis. Establishing BESP involves management’s judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the agreement. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. The allocated consideration for each unit of accounting is recognized over the related obligation period in accordance with the applicable revenue recognition criteria. If there are deliverables in an arrangement that are not separable from other aspects of the contractual relationship, they are treated as a combined unit of accounting, with the allocated revenue for the combined unit recognized in a manner consistent with the revenue recognition applicable to the final deliverable in the combined unit. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as unearned revenue in the accompanying balance sheets and recognized as revenue when the related revenue recognition criteria are met. The Company typically receives up-front payments when licensing its intellectual property, which often occurs in conjunction with a R&D agreement. The Company recognizes revenue attributed to the license upon delivery, provided that the license has stand-alone value. For payments payable on achievement of milestones that do not meet all of the conditions to be considered substantive, the Company recognizes the portion of the payment allocable to delivered items as revenue when the specific milestone is achieved, and the contingency is removed. Prior to the revised multiple element guidance described above, adopted by the Company on January 1, 2011, upfront, nonrefundable payments for license fees, grants, and advance payments for sponsored research revenues received in excess of amounts earned were classified as deferred revenue and recognized as income over the contract or development period. Revenues from development milestones are accounted for in accordance with the Revenue Recognition – Milestone Method Topic of the FASB ASC (Milestone Method). Milestones are recognized when earned, as evidenced by written acknowledgment from the collaborator or other persuasive evidence that the milestone has been achieved, provided that the milestone event is substantive. A milestone event is considered to be substantive if its achievability was not reasonably assured at the inception of the agreement and the Company’s efforts led to the achievement of the milestone or the milestone was due upon the occurrence of a specific outcome resulting from the Company’s performance. The Company assesses whether a milestone is substantive at the inception of each agreement. Mitsubishi Tanabe Pharma Corporation (Mitsubishi Tanabe). Under the terms of the Company’s agreement with Mitsubishi Tanabe, the collaboration effort between the parties to advance NBI-98854 towards commercialization in Japan and other select Asian markets is governed by a joint steering committee and joint development committee with representatives from both the Company and Mitsubishi Tanabe. There are no performance, cancellation, termination or refund provisions in the agreement that would have a material financial consequence to the Company. The Company does not directly control when event-based payments will be achieved or when royalty payments will begin. Mitsubishi Tanabe may terminate the agreement at its discretion upon 180 days’ written notice to the Company. In such event, all valbenazine product rights for Japan and other select Asian markets would revert to the Company. The Company has identified the following deliverables associated with the Mitsubishi Tanabe agreement: valbenazine technology license and existing know-how, development activities to be performed as part of the collaboration, and the manufacture of pharmaceutical products. The respective standalone value from each of these deliverables has been determined by applying the BESP method and the revenue was allocated based on the relative selling price method with revenue recognition timing to be determined either by delivery or the provision of services. As discussed above, the BESP method required the use of significant estimates. The Company used an income approach to estimate the selling price for the technology license and an expense approach for estimating development activities and the manufacture of pharmaceutical products. The development activities and the manufacture of pharmaceutical products are expected to be delivered throughout the duration of the agreement. The technology license and existing know-how was delivered on the effective date of the agreement. For the three months ended March 31, 2015, the Company recognized revenue under this agreement of $19.8 million associated with the delivery of a technology license and existing know-how. In accordance with the Company’s continuing performance obligations, $10.2 million of the $30 million up-front payment is being deferred and recognized in future periods. Under the terms of the agreement, there is no general obligation to return the up-front payment for any non-contingent deliverable. The Company evaluated the event-based payments under the Milestone Method and concluded only one immaterial event-based payment represents a substantive milestone. Event-based payments will be recognized when earned. The Company is eligible to receive from Mitsubishi Tanabe tiered royalty payments based on product sales in Japan and other select Asian markets. Royalties will be recognized as earned in accordance with the terms of the agreement, when product sales are reported by Mitsubishi Tanabe, the amount can be reasonably estimated, and collectability is reasonably assured. AbbVie Inc. ( AbbVie ) Under the terms of the agreement, AbbVie is responsible for all third-party development, marketing and commercialization costs. The Company will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights. AbbVie may terminate the collaboration at its discretion upon 180 days’ written notice to the Company. In such event, the Company would be entitled to specified payments for ongoing clinical development and related activities and all GnRH Compound product rights would revert to the Company. During the three months ended March 31, 2016, the Company recognized $15 million in development event based payments resulting from AbbVie initiating Phase III development of elagolix in uterine fibroids.

INVESTMENTS

INVESTMENTS	3 Months Ended
	Mar. 31, 2016
Investments Schedule [Abstract]
INVESTMENTS	3. INVESTMENTS Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in comprehensive loss. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income or expense. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income. Investments consist of the following ( in thousands March 31, December 31, Certificates of deposit $ 7,445 $ 10,078 Commercial paper 11,991 23,955 Corporate debt securities 251,857 323,219 Securities of government sponsored entities 44,390 30,232 Total investments $ 315,683 $ 387,484 The following is a summary of investments classified as available-for-sale securities ( in thousands Contractual Amortized Gross Gross Aggregate March 31, 2016: Classified as current assets: Certificates of deposit Less than 1 $ 7,200 $ 4 $ — $ 7,204 Commercial paper Less than 1 11,989 2 — 11,991 Corporate debt securities Less than 1 225,310 72 (217 ) 225,165 Securities of government-sponsored entities Less than 1 21,863 2 (2 ) 21,863 Total short-term available-for-sale securities $ 266,362 $ 80 $ (219 ) $ 266,223 Classified as non-current assets: Certificates of deposit 1 to 2 $ 240 $ 1 $ — $ 241 Corporate debt securities 1 to 2 26,721 29 (58 ) 26,692 Securities of government-sponsored entities 1 to 2 22,548 — (21 ) 22,527 Total long-term available-for-sale securities $ 49,509 $ 30 $ (79 ) $ 49,460 December 31, 2015: Classified as current assets: Certificates of deposit Less than 1 $ 9,120 $ 1 $ (1 ) $ 9,120 Commercial paper Less than 1 23,965 1 (11 ) 23,955 Corporate debt securities Less than 1 254,592 1 (414 ) 254,179 Securities of government-sponsored entities Less than 1 17,762 1 (21 ) 17,742 Total short-term available-for-sale securities $ 305,439 $ 4 $ (447 ) $ 304,996 Classified as non-current assets: Certificates of deposit 1 to 2 $ 960 $ — $ (2 ) $ 958 Corporate debt securities 1 to 2 69,528 — (488 ) 69,040 Securities of government-sponsored entities 1 to 2 12,534 — (44 ) 12,490 Total long-term available-for-sale securities $ 83,022 $ — $ (534 ) $ 82,488 (1) Unrealized gains and losses are included in other comprehensive loss. The following table presents gross unrealized losses and fair value for those available-for-sale investments that were in an unrealized loss position as of March 31, 2016 and December 31, 2015, aggregated by investment category and length of time that individual securities have been in a continuous loss position ( in thousands Less Than 12 Months 12 Months or Greater Total Estimated Unrealized Estimated Unrealized Estimated Unrealized March 31, 2016: Corporate debt securities $ 138,427 $ (270 ) $ 5,074 $ (5 ) $ 143,501 $ (275 ) Securities of government-sponsored entities 34,485 (23 ) — — 34,485 (23 ) Total $ 172,912 $ (293 ) $ 5,074 $ (5 ) $ 177,986 $ (298 ) December 31, 2015: Certificates of deposit $ 5,517 $ (3 ) $ — $ — $ 5,517 $ (3 ) Commercial paper 16,959 (11 ) — — 16,959 (11 ) Corporate debt securities 310,160 (880 ) 5,521 (22 ) 315,681 (902 ) Securities of government-sponsored entities 25,913 (65 ) — — 25,913 (65 ) Total $ 358,549 $ (959 ) $ 5,521 $ (22 ) $ 364,070 $ (981 ) The primary objective of the Company’s investment portfolio is to enhance overall returns in an efficient manner while maintaining safety of principal, prudent levels of liquidity and acceptable levels of risk. The Company’s investment policy limits interest-bearing security investments to certain types of instruments issued by institutions with primarily investment grade credit ratings and places restrictions on maturities and concentration by asset class and issuer. The Company reviews the available-for-sale investments for other-than-temporary declines in fair value below cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. This evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below the cost basis and adverse conditions related specifically to the security, including any changes to the credit rating of the security, and the intent to sell, or whether the Company will more likely than not be required to sell the security before recovery of its amortized cost basis. The assessment of whether a security is other-than-temporarily impaired could change in the future due to new developments or changes in assumptions related to any particular security. As of March 31, 2016 and December 31, 2015, the Company believed the cost bases for available-for-sale investments were recoverable in all material respects.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	4. FAIR VALUE MEASUREMENTS Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets; Level 2: Inputs include quoted prices for similar instruments in active markets and/or quoted prices for identical or similar instruments in markets that are not active near the measurement date; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company classifies its cash equivalents and available for sale investments within Level 1 or Level 2. The fair value of the Company’s high quality investment grade corporate debt securities is determined using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company did not reclassify any investments between levels in the fair value hierarchy during the three months ended March 31, 2016. The Company’s assets which were measured at fair value on a recurring basis as of March 31, 2016 and December 31, 2015 were determined using the inputs described above and are as follows ( in millions Fair Value Measurements Using Carrying Quoted Prices in Significant Other Significant March 31, 2016: Classified as current assets: Cash and money market funds $ 105.4 $ 105.4 $ — $ — Certificates of deposit 7.2 7.2 — — Commercial paper 12.0 — 12.0 — Securities of government-sponsored entities 21.9 — 21.9 — Corporate debt securities 235.3 — 235.3 — Subtotal 381.8 112.6 269.2 — Classified as long-term assets: Certificates of deposit 5.0 5.0 — — Corporate debt securities 26.7 — 26.7 — Securities of government-sponsored entities 22.5 — 22.5 — Total 436.0 117.6 318.4 — Less cash, cash equivalents and restricted cash (120.3 ) (110.1 ) (10.2 ) — Total investments $ 315.7 $ 7.5 $ 308.2 $ — December 31, 2015: Classified as current assets: Cash and money market funds $ 69.5 $ 69.5 $ — $ — Certificates of deposit 9.1 9.1 — — Commercial paper 24.0 — 24.0 — Securities of government-sponsored entities 17.7 — 17.7 — Corporate debt securities 259.0 — 259.0 — Subtotal 379.3 78.6 300.7 — Classified as long-term assets: Certificates of deposit 5.7 5.7 — — Securities of government-sponsored entities 12.5 — 12.5 — Corporate debt securities 69.0 — 69.0 — Total 466.5 84.3 382.2 — Less cash, cash equivalents and restricted cash (79.0 ) (74.2 ) (4.8 ) — Total investments $ 387.5 $ 10.1 $ 377.4 $ —

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
SHARE-BASED COMPENSATION	5. SHARE-BASED COMPENSATION The compensation expense related to the Company’s share-based compensation arrangements has been included in the condensed consolidated statements of comprehensive loss as follows ( in millions Three Months Ended 2016 2015 General and administrative $ 4.1 $ 1.7 Research and development 2.8 1.9 Total share-based compensation expense $ 6.9 $ 3.6 The fair value of equity instruments that vest based on continued employee service, net of estimated forfeitures, is recognized and amortized on a straight-line basis over the requisite service period. For restricted stock units (RSUs) with performance-based vesting requirements (PRSUs), no expense is recorded until the performance condition is probable of being achieved. The Company estimates forfeiture rates for equity awards based on past behavior for similar equity awards with further consideration given to the class of employees to whom the equity awards were granted. As of March 31, 2016, total unrecognized estimated compensation cost related to non-vested stock options and non-vested RSUs, that vest over a given service period, granted prior to that date was $38.1 million and $25.0 million, respectively, which is expected to be recognized over a weighted average period of approximately 3.0 years. Additionally, the Company has approximately 0.4 million PRSUs outstanding. The total unrecognized estimated compensation cost related to these PRSUs is $10.1 million and is recognized over the expected performance period once the achievement of performance conditions becomes probable. During the three months ended March 31, 2016 and 2015, stock options to purchase approximately 26,000 and 0.7 million shares of the Company’s common stock were exercised, respectively. The cash received by the Company from stock option exercises during the three months ended March 31, 2016 and 2015 was approximately $0.1 million and $2.8 million, respectively. The Company also issued approximately 0.3 million and 0.2 million shares of common stock pursuant to the vesting of RSUs during the three months ended March 31, 2016 and 2015, respectively. Stock Option Assumptions The Company granted stock options to purchase approximately 0.7 million and 0.7 million shares of the Company’s common stock during the three months ended March 31, 2016 and 2015, respectively. These stock options generally vest monthly over a four-year period. The exercise price of all stock options granted during the three months ended March 31, 2016 and 2015 was equal to the closing price of the Company’s common stock on the date of grant. The estimated fair value of each stock option granted was determined on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions for the stock option grants: Three Months Ended 2016 2015 Risk-free interest rate 1.4% 1.6% Expected volatility of common stock 60.0% 66.6% Dividend yield 0.0% 0.0% Expected option term 5.6 years 6.7 years The Black-Scholes option-pricing model incorporates various and highly sensitive assumptions including expected volatility, expected term and interest rates. The expected volatility is based on the historical volatility of the Company’s common stock over the most recent period commensurate with the estimated expected term of the Company’s stock options. The expected option term is estimated based on historical experience as well as the status of the employee. For example, directors and officers have a longer expected option term than all other employees. The risk-free rate for periods within the contractual life of the option is based upon observed interest rates appropriate for the expected term of the Company’s employee stock options. The Company has never declared or paid dividends and has no plans to do so in the foreseeable future. For the three months ended March 31, 2016 and 2015, share-based compensation expense related to stock options was $4.4 million and $2.4 million, respectively. Restricted Stock Units During the three months ended March 31, 2016 and 2015, the Company granted approximately 0.3 million and 0.4 million RSUs, respectively, that vest annually over a four year period. Additionally, during the three months ended March 31, 2016 and 2015, the Company granted approximately 230,000 and 50,000 PRSUs, respectively. These PRSUs vest based on the achievement of pre-defined Company-specific performance criteria and expire approximately four to five years from the grant date. Expense recognition for PRSUs commences when attainment of the performance based criteria is probable. The fair value of RSUs and PRSUs is estimated based on the closing sale price of the Company’s common stock on the date of grant. For the three months ended March 31, 2016 and 2015, the aggregate share-based compensation expense related to RSUs and PRSUs was $2.5 million and $1.2 million, respectively.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
STOCKHOLDERS' EQUITY	6. STOCKHOLDERS’ EQUITY Equity Financing In February 2015, the Company completed a public offering of common stock in which the Company sold 8.0 million shares of its common stock at an offering price of $36.00 per share. The net proceeds generated from this transaction, after underwriting discounts and commissions and offering costs, were approximately $270.7 million. Shelf Registration Statements In February 2014, the Company filed an automatic shelf registration statement which immediately became effective by rule of the SEC. For so long as the Company continues to satisfy the requirements to be deemed a well-known seasoned issuer, this shelf registration statement allows the Company to issue an unlimited number of shares of its common stock from time to time. As of March 31, 2016, the Company had sold 16.0 million shares under this shelf registration statement. The specific terms of future offerings, if any, under any of the shelf registration statements would be established at the time of such offerings.

REAL ESTATE

REAL ESTATE	3 Months Ended
	Mar. 31, 2016
Leases [Abstract]
REAL ESTATE	7. REAL ESTATE In December 2007, the Company closed the sale of its facility and associated real property for a purchase price of $109 million. Concurrent with the sale, the Company retired the entire $47.7 million in mortgage debt previously outstanding with respect to the facility and associated real property, and received cash of $61.0 million net of transaction costs and debt retirement. Upon the closing of the sale of the facility and associated real property, the Company entered into a lease agreement (Lease) whereby it leased back for an initial term of 12 years its corporate headquarters comprised of two buildings located at 12790 El Camino Real (Front Building) and 12780 El Camino Real (Rear Building) in San Diego, California. The Company also entered into a series of lease amendments (Amendments), beginning in late 2008, through which it vacated the Front Building, but continues to occupy the Rear Building. The ultimate result of this real estate sale was a net gain of $39.1 million which was deferred in accordance with authoritative guidance. The Company recognized $0.9 million and $0.8 million of the deferred gain during the three month periods ending March 31, 2016 and 2015, respectively, and will recognize the remaining $13.5 million of the deferred gain over the initial Lease term which will expire at the end of 2019. Under the terms of the Lease and the Amendments, the Company pays base annual rent (subject to an annual fixed percentage increase), plus a 3.5% annual management fee, property taxes and other normal and necessary expenses associated with the Lease such as utilities, repairs and maintenance. In lieu of a cash security deposit under the Lease, Wells Fargo Bank, N.A. issued on the Company’s behalf a letter of credit in the amount of $4.6 million, which is secured by a deposit of equal amount with the same bank. The Company also has the right to extend the Lease for two consecutive ten-year terms. As of March 31, 2016, the Company had two sublease agreements for approximately 30,000 square feet of the Rear Building. These subleases were expected to result in approximately $1.1 million of rental income in 2016 with this sublease rental income being recorded as an offset to rent expense. The income generated under these subleases is lower than the Company’s financial obligation under the Lease for the Rear Building, as determined on a per square foot basis. Consequently, at the inception of such a sublease, or in association with an amendment to such sublease, the Company is required to record a cease-use liability for the net present value of the estimated difference between the expected income to be generated under the subleases and future subleases and the Lease obligation over the remaining term of the Lease for the space that is occupied by the subtenant. The subleases provide various options to extend for additional one-year renewal periods. During the first quarter of 2016, the Company agreed to terminate one sublease early and began to reoccupy the space under the sublease to allow for expansion. This resulted in reversal of cease use expense of approximately $0.8 million and a corresponding increase in deferred rent of approximately $0.2 million during the first quarter of 2016. The current term of the remaining sublease is scheduled to expire in March 2018 and is expected to generate approximately $0.6 million in rental income during 2016. The following table sets forth changes to the accrued cease-use liability during the three months ended March 31, 2016 and 2015 ( in thousands Three Months Ended 2016 2015 Beginning balance $ 1,983 $ 2,678 Change in estimate (1) (830 ) — Payments (110 ) (113 ) Ending balance $ 1,043 $ 2,565 (1) Change in estimate was offset by an increase in deferred rent of approximately $246,000 during the first quarter of 2016.

LOSS PER COMMON SHARE

LOSS PER COMMON SHARE	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
LOSS PER COMMON SHARE	8. LOSS PER COMMON SHARE The Company computes basic net loss per share using the weighted average number of common shares outstanding during the period. In computing the diluted net loss, potentially dilutive securities, composed of incremental common shares issuable upon the exercise of stock options and warrants and the vesting of RSUs and PRSUs, are excluded from the diluted loss per share calculation because of their anti-dilutive effect. For the three months ended March 31, 2016, the Company realized a net loss of $19.3 million. Potentially dilutive securities totaled approximately 3.6 million for the three months ended March 31, 2016. Options to purchase approximately 0.5 million shares of common stock were outstanding during the three months ended March 31, 2016 with an exercise price greater than the average market price of the underlying common shares. For the three months ended March 31, 2015, the Company realized a net loss of $1.2 million. Potentially dilutive securities totaled approximately 3.9 million for the three months ended March 31, 2015. Options to purchase approximately 0.1 million shares of common stock were outstanding during the three months ended March 31, 2015 with an exercise price greater than the average market price of the underlying common shares.

RESEARCH AND DEVELOPMENT

RESEARCH AND DEVELOPMENT	3 Months Ended
	Mar. 31, 2016
Research and Development [Abstract]
RESEARCH AND DEVELOPMENT	9. RESEARCH AND DEVELOPMENT R&D expenses consist primarily of salaries, payroll taxes, employee benefits, and share-based compensation charges, for those individuals involved in ongoing R&D efforts; as well as scientific contractor fees, preclinical and clinical trial costs, R&D facilities costs, laboratory supply costs, and depreciation of scientific equipment. All such costs are charged to R&D expense as incurred. These expenses result from the Company’s independent R&D efforts as well as efforts associated with collaborations and in-licensing arrangements. In addition, the Company funds R&D at other companies and research institutions under agreements, which are generally cancelable. The Company reviews and accrues clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of patient studies and other events. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.

LITIGATION DISCLOSURE

LITIGATION DISCLOSURE	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
LITIGATION DISCLOSURE	10. LITIGATION DISCLOSURE On December 1, 2015, Icahn School of Medicine at Mount Sinai (Mount Sinai) filed a complaint against the Company in the United States District Court for the Southern District of New York: Icahn School of Medicine at Mount Sinai v. Neurocrine Biosciences, Inc. No. 1:15-cv-09414.

ORGANIZATION AND SIGNIFICANT 16

ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Description of Business	Description of Business.
Basis of Presentation	Basis of Presentation These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The balance sheet at December 31, 2015 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.
Impact of Recently Issued Accounting Standards	Impact of Recently Issued Accounting Standards In February 2016, the FASB issued Accounting Standards Update 2016-02 Leases. This update amends the current accounting guidance for lease transactions. Under the new guidance, a lessee will be required to recognize both assets and liabilities for any leases in excess of twelve months. Additionally, certain qualitative and quantitative disclosures will also be required in the financial statements. The Company is required to adopt this new guidance beginning in 2019 and early adoption is permitted. The Company is in the process of determining the effects the adoption of this update will have on its consolidated financial statements. In March 2016, the FASB issued Accounting Standards Update 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This update amends the current tax accounting rules for share-based compensation in an attempt to simplify the reporting of excess tax benefits and deficiencies related to equity compensation. Additionally, the FASB has provided an alternative for forfeiture estimations related to grants of equity awards. We are required to adopt this new guidance beginning in 2017 and early adoption is permitted. The Company is in the process of determining the effects the adoption of this update will have on its consolidated financial statements.
Use of Estimates	Use of Estimates
Revenue Recognition Policy	Revenue Recognition Policy. The Company recognizes revenue for the performance of services when each of the following four criteria is met: (i) persuasive evidence of an arrangement exists; (ii) services are rendered or products are delivered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured. Since 2011, the Company has followed the Accounting Standards Codification (ASC) for Revenue Recognition—Multiple-Element Arrangements, if applicable, to determine the recognition of revenue under license and collaboration agreements. The terms of these agreements generally contain multiple elements, or deliverables, which may include (i) licenses to the Company’s intellectual property, (ii) materials and technology, (iii) pharmaceutical supply, (iv) participation on joint development or joint steering committees, and (v) development services. The payments the Company receives under these arrangements typically include one or more of the following: up-front license fees; funding of research and/or development efforts; amounts due upon the achievement of specified milestones; manufacturing and royalties on future product sales. The ASC provides guidance relating to the separation of deliverables included in an arrangement into different units of accounting and the allocation of consideration to the units of accounting. The evaluation of multiple-element arrangements requires management to make judgments about (i) the identification of deliverables, (ii) whether such deliverables are separable from the other aspects of the contractual relationship, (iii) the estimated selling price of each deliverable, and (iv) the expected period of performance for each deliverable. To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances for each arrangement. The selling prices of deliverables under an arrangement may be derived using vendor specific objective evidence (VSOE), third-party evidence, or a best estimate of selling price (BESP), if VSOE or third-party evidence is not available. For most pharmaceutical licensing and collaboration agreements, BESP is utilized. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the agreement was sold on a standalone basis. Establishing BESP involves management’s judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the agreement. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. The allocated consideration for each unit of accounting is recognized over the related obligation period in accordance with the applicable revenue recognition criteria. If there are deliverables in an arrangement that are not separable from other aspects of the contractual relationship, they are treated as a combined unit of accounting, with the allocated revenue for the combined unit recognized in a manner consistent with the revenue recognition applicable to the final deliverable in the combined unit. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as unearned revenue in the accompanying balance sheets and recognized as revenue when the related revenue recognition criteria are met. The Company typically receives up-front payments when licensing its intellectual property, which often occurs in conjunction with a R&D agreement. The Company recognizes revenue attributed to the license upon delivery, provided that the license has stand-alone value. For payments payable on achievement of milestones that do not meet all of the conditions to be considered substantive, the Company recognizes the portion of the payment allocable to delivered items as revenue when the specific milestone is achieved, and the contingency is removed. Prior to the revised multiple element guidance described above, adopted by the Company on January 1, 2011, upfront, nonrefundable payments for license fees, grants, and advance payments for sponsored research revenues received in excess of amounts earned were classified as deferred revenue and recognized as income over the contract or development period. Revenues from development milestones are accounted for in accordance with the Revenue Recognition – Milestone Method Topic of the FASB ASC (Milestone Method). Milestones are recognized when earned, as evidenced by written acknowledgment from the collaborator or other persuasive evidence that the milestone has been achieved, provided that the milestone event is substantive. A milestone event is considered to be substantive if its achievability was not reasonably assured at the inception of the agreement and the Company’s efforts led to the achievement of the milestone or the milestone was due upon the occurrence of a specific outcome resulting from the Company’s performance. The Company assesses whether a milestone is substantive at the inception of each agreement. Mitsubishi Tanabe Pharma Corporation (Mitsubishi Tanabe). Under the terms of the Company’s agreement with Mitsubishi Tanabe, the collaboration effort between the parties to advance NBI-98854 towards commercialization in Japan and other select Asian markets is governed by a joint steering committee and joint development committee with representatives from both the Company and Mitsubishi Tanabe. There are no performance, cancellation, termination or refund provisions in the agreement that would have a material financial consequence to the Company. The Company does not directly control when event-based payments will be achieved or when royalty payments will begin. Mitsubishi Tanabe may terminate the agreement at its discretion upon 180 days’ written notice to the Company. In such event, all valbenazine product rights for Japan and other select Asian markets would revert to the Company. The Company has identified the following deliverables associated with the Mitsubishi Tanabe agreement: valbenazine technology license and existing know-how, development activities to be performed as part of the collaboration, and the manufacture of pharmaceutical products. The respective standalone value from each of these deliverables has been determined by applying the BESP method and the revenue was allocated based on the relative selling price method with revenue recognition timing to be determined either by delivery or the provision of services. As discussed above, the BESP method required the use of significant estimates. The Company used an income approach to estimate the selling price for the technology license and an expense approach for estimating development activities and the manufacture of pharmaceutical products. The development activities and the manufacture of pharmaceutical products are expected to be delivered throughout the duration of the agreement. The technology license and existing know-how was delivered on the effective date of the agreement. For the three months ended March 31, 2015, the Company recognized revenue under this agreement of $19.8 million associated with the delivery of a technology license and existing know-how. In accordance with the Company’s continuing performance obligations, $10.2 million of the $30 million up-front payment is being deferred and recognized in future periods. Under the terms of the agreement, there is no general obligation to return the up-front payment for any non-contingent deliverable. The Company evaluated the event-based payments under the Milestone Method and concluded only one immaterial event-based payment represents a substantive milestone. Event-based payments will be recognized when earned. The Company is eligible to receive from Mitsubishi Tanabe tiered royalty payments based on product sales in Japan and other select Asian markets. Royalties will be recognized as earned in accordance with the terms of the agreement, when product sales are reported by Mitsubishi Tanabe, the amount can be reasonably estimated, and collectability is reasonably assured. AbbVie Inc. ( AbbVie ) Under the terms of the agreement, AbbVie is responsible for all third-party development, marketing and commercialization costs. The Company will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights. AbbVie may terminate the collaboration at its discretion upon 180 days’ written notice to the Company. In such event, the Company would be entitled to specified payments for ongoing clinical development and related activities and all GnRH Compound product rights would revert to the Company. During the three months ended March 31, 2016, the Company recognized $15 million in development event based payments resulting from AbbVie initiating Phase III development of elagolix in uterine fibroids.

INVESTMENTS (Tables)

INVESTMENTS (Tables)	3 Months Ended
	Mar. 31, 2016
Investments Schedule [Abstract]
Investments	Investments consist of the following ( in thousands March 31, December 31, Certificates of deposit $ 7,445 $ 10,078 Commercial paper 11,991 23,955 Corporate debt securities 251,857 323,219 Securities of government sponsored entities 44,390 30,232 Total investments $ 315,683 $ 387,484
Summary of Investments Classified as Available-For-Sale Securities	The following is a summary of investments classified as available-for-sale securities ( in thousands Contractual Amortized Gross Gross Aggregate March 31, 2016: Classified as current assets: Certificates of deposit Less than 1 $ 7,200 $ 4 $ — $ 7,204 Commercial paper Less than 1 11,989 2 — 11,991 Corporate debt securities Less than 1 225,310 72 (217 ) 225,165 Securities of government-sponsored entities Less than 1 21,863 2 (2 ) 21,863 Total short-term available-for-sale securities $ 266,362 $ 80 $ (219 ) $ 266,223 Classified as non-current assets: Certificates of deposit 1 to 2 $ 240 $ 1 $ — $ 241 Corporate debt securities 1 to 2 26,721 29 (58 ) 26,692 Securities of government-sponsored entities 1 to 2 22,548 — (21 ) 22,527 Total long-term available-for-sale securities $ 49,509 $ 30 $ (79 ) $ 49,460 December 31, 2015: Classified as current assets: Certificates of deposit Less than 1 $ 9,120 $ 1 $ (1 ) $ 9,120 Commercial paper Less than 1 23,965 1 (11 ) 23,955 Corporate debt securities Less than 1 254,592 1 (414 ) 254,179 Securities of government-sponsored entities Less than 1 17,762 1 (21 ) 17,742 Total short-term available-for-sale securities $ 305,439 $ 4 $ (447 ) $ 304,996 Classified as non-current assets: Certificates of deposit 1 to 2 $ 960 $ — $ (2 ) $ 958 Corporate debt securities 1 to 2 69,528 — (488 ) 69,040 Securities of government-sponsored entities 1 to 2 12,534 — (44 ) 12,490 Total long-term available-for-sale securities $ 83,022 $ — $ (534 ) $ 82,488 (1) Unrealized gains and losses are included in other comprehensive loss.
Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position	The following table presents gross unrealized losses and fair value for those available-for-sale investments that were in an unrealized loss position as of March 31, 2016 and December 31, 2015, aggregated by investment category and length of time that individual securities have been in a continuous loss position ( in thousands Less Than 12 Months 12 Months or Greater Total Estimated Unrealized Estimated Unrealized Estimated Unrealized March 31, 2016: Corporate debt securities $ 138,427 $ (270 ) $ 5,074 $ (5 ) $ 143,501 $ (275 ) Securities of government-sponsored entities 34,485 (23 ) — — 34,485 (23 ) Total $ 172,912 $ (293 ) $ 5,074 $ (5 ) $ 177,986 $ (298 ) December 31, 2015: Certificates of deposit $ 5,517 $ (3 ) $ — $ — $ 5,517 $ (3 ) Commercial paper 16,959 (11 ) — — 16,959 (11 ) Corporate debt securities 310,160 (880 ) 5,521 (22 ) 315,681 (902 ) Securities of government-sponsored entities 25,913 (65 ) — — 25,913 (65 ) Total $ 358,549 $ (959 ) $ 5,521 $ (22 ) $ 364,070 $ (981 )

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Assets Measured at Fair Value on Recurring Basis	The Company’s assets which were measured at fair value on a recurring basis as of March 31, 2016 and December 31, 2015 were determined using the inputs described above and are as follows ( in millions Fair Value Measurements Using Carrying Quoted Prices in Significant Other Significant March 31, 2016: Classified as current assets: Cash and money market funds $ 105.4 $ 105.4 $ — $ — Certificates of deposit 7.2 7.2 — — Commercial paper 12.0 — 12.0 — Securities of government-sponsored entities 21.9 — 21.9 — Corporate debt securities 235.3 — 235.3 — Subtotal 381.8 112.6 269.2 — Classified as long-term assets: Certificates of deposit 5.0 5.0 — — Corporate debt securities 26.7 — 26.7 — Securities of government-sponsored entities 22.5 — 22.5 — Total 436.0 117.6 318.4 — Less cash, cash equivalents and restricted cash (120.3 ) (110.1 ) (10.2 ) — Total investments $ 315.7 $ 7.5 $ 308.2 $ — December 31, 2015: Classified as current assets: Cash and money market funds $ 69.5 $ 69.5 $ — $ — Certificates of deposit 9.1 9.1 — — Commercial paper 24.0 — 24.0 — Securities of government-sponsored entities 17.7 — 17.7 — Corporate debt securities 259.0 — 259.0 — Subtotal 379.3 78.6 300.7 — Classified as long-term assets: Certificates of deposit 5.7 5.7 — — Securities of government-sponsored entities 12.5 — 12.5 — Corporate debt securities 69.0 — 69.0 — Total 466.5 84.3 382.2 — Less cash, cash equivalents and restricted cash (79.0 ) (74.2 ) (4.8 ) — Total investments $ 387.5 $ 10.1 $ 377.4 $ —

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Compensation Expenses Related to Share Based Compensation	The compensation expense related to the Company’s share-based compensation arrangements has been included in the condensed consolidated statements of comprehensive loss as follows ( in millions Three Months Ended 2016 2015 General and administrative $ 4.1 $ 1.7 Research and development 2.8 1.9 Total share-based compensation expense $ 6.9 $ 3.6
Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model	The estimated fair value of each stock option granted was determined on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions for the stock option grants: Three Months Ended 2016 2015 Risk-free interest rate 1.4% 1.6% Expected volatility of common stock 60.0% 66.6% Dividend yield 0.0% 0.0% Expected option term 5.6 years 6.7 years

REAL ESTATE (Tables)

REAL ESTATE (Tables)	3 Months Ended
	Mar. 31, 2016
Leases [Abstract]
Changes to Accrued Cease-Use Liability	The following table sets forth changes to the accrued cease-use liability during the three months ended March 31, 2016 and 2015 ( in thousands Three Months Ended 2016 2015 Beginning balance $ 1,983 $ 2,678 Change in estimate (1) (830 ) — Payments (110 ) (113 ) Ending balance $ 1,043 $ 2,565 (1) Change in estimate was offset by an increase in deferred rent of approximately $246,000 during the first quarter of 2016.

Revenue Recognition and Signi21

Revenue Recognition and Significant Collaborative Research and Development Agreements - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Jun. 30, 2010	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Mitsubishi Tanabe
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement upfront payment received				$ 30,000,000
Collaborative agreement maximum additional payment to receive				85,000,000
Patent rights period		The longer of ten years or the life of the related patent rights.
Clinical trial cost				$ 12,000,000
Collaborative arrangement right description		Under the terms of the Company’s agreement with Mitsubishi Tanabe, the collaboration effort between the parties to advance NBI-98854 towards commercialization is governed by a joint steering committee and joint development committee with representatives from both the Company and Mitsubishi Tanabe. There are no performance, cancellation, termination or refund provisions in the agreement that would have a material financial consequence to the Company. The Company does not directly control when milestones will be achieved or when royalty payments will begin. Mitsubishi Tanabe may terminate the collaboration at its discretion upon 180 days’ written notice to the Company.
Collaboration termination notice period		180 days
Revenues recognized under collaboration agreement			$ 19,800,000
Deferred revenues under collaboration			$ 10,200,000
AbbVie
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement upfront payment received	$ 75,000,000
Patent rights period		Ten years or the life of the related patent rights.
Collaborative arrangement right description		The Company will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights.
Collaboration termination notice period		180 days
Amount remains outstanding under collaboration agreement		$ 485,000,000
Payment of clinical development recognized		15,000,000
AbbVie | Development and regulatory event based payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement maximum additional payment to receive		480,000,000
Collaborative agreement payment earned		45,000,000
AbbVie | Commercial event based payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement maximum additional payment to receive		$ 50,000,000

Investments (Detail)

Investments (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Schedule of Investments [Line Items]
Investments	$ 315,683	$ 387,484
Certificates of deposit
Schedule of Investments [Line Items]
Investments	7,445	10,078
Commercial paper
Schedule of Investments [Line Items]
Investments	11,991	23,955
Corporate debt securities
Schedule of Investments [Line Items]
Investments	251,857	323,219
Securities of government sponsored entities
Schedule of Investments [Line Items]
Investments	$ 44,390	$ 30,232

Summary of Investments Classifi

Summary of Investments Classified as Available-For-Sale Securities (Detail) - USD ($) $ in Thousands		3 Months Ended	12 Months Ended
		Mar. 31, 2016	Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Aggregate Estimated Fair Value		$ 315,683	$ 387,484
Certificates of deposit
Schedule of Available-for-sale Securities [Line Items]
Aggregate Estimated Fair Value		7,445	10,078
Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Aggregate Estimated Fair Value		11,991	23,955
Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Aggregate Estimated Fair Value		251,857	323,219
Securities of government sponsored entities
Schedule of Available-for-sale Securities [Line Items]
Aggregate Estimated Fair Value		44,390	30,232
Short-term investments
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		266,362	305,439
Gross Unrealized Gains	[1]	80	4
Gross Unrealized Losses	[1]	(219)	(447)
Aggregate Estimated Fair Value		266,223	304,996
Short-term investments | Certificates of deposit
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		7,200	9,120
Gross Unrealized Gains	[1]	4	1
Gross Unrealized Losses	[1]	0	(1)
Aggregate Estimated Fair Value		$ 7,204	$ 9,120
Short-term investments | Certificates of deposit | Maximum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity		1 year	1 year
Short-term investments | Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		$ 11,989	$ 23,965
Gross Unrealized Gains	[1]	2	1
Gross Unrealized Losses	[1]	0	(11)
Aggregate Estimated Fair Value		$ 11,991	$ 23,955
Short-term investments | Commercial paper | Maximum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity		1 year	1 year
Short-term investments | Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		$ 225,310	$ 254,592
Gross Unrealized Gains	[1]	72	1
Gross Unrealized Losses	[1]	(217)	(414)
Aggregate Estimated Fair Value		$ 225,165	$ 254,179
Short-term investments | Corporate debt securities | Maximum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity		1 year	1 year
Short-term investments | Securities of government sponsored entities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		$ 21,863	$ 17,762
Gross Unrealized Gains	[1]	2	1
Gross Unrealized Losses	[1]	(2)	(21)
Aggregate Estimated Fair Value		$ 21,863	$ 17,742
Short-term investments | Securities of government sponsored entities | Maximum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity		1 year	1 year
Long-term investments
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		$ 49,509	$ 83,022
Gross Unrealized Gains	[1]	30	0
Gross Unrealized Losses	[1]	(79)	(534)
Aggregate Estimated Fair Value		49,460	82,488
Long-term investments | Certificates of deposit
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		240	960
Gross Unrealized Gains	[1]	1	0
Gross Unrealized Losses	[1]	0	(2)
Aggregate Estimated Fair Value		$ 241	$ 958
Long-term investments | Certificates of deposit | Minimum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity		1 year	1 year
Long-term investments | Certificates of deposit | Maximum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity		2 years	2 years
Long-term investments | Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		$ 26,721	$ 69,528
Gross Unrealized Gains	[1]	29	0
Gross Unrealized Losses	[1]	(58)	(488)
Aggregate Estimated Fair Value		$ 26,692	$ 69,040
Long-term investments | Corporate debt securities | Minimum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity		1 year	1 year
Long-term investments | Corporate debt securities | Maximum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity		2 years	2 years
Long-term investments | Securities of government sponsored entities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		$ 22,548	$ 12,534
Gross Unrealized Gains	[1]	0	0
Gross Unrealized Losses	[1]	(21)	(44)
Aggregate Estimated Fair Value		$ 22,527	$ 12,490
Long-term investments | Securities of government sponsored entities | Minimum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity		1 year	1 year
Long-term investments | Securities of government sponsored entities | Maximum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity		2 years	2 years
[1]	(1) Unrealized gains and losses are included in other comprehensive loss.

Gross Unrealized Losses and Fai

Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Estimated Fair Value	$ 172,912	$ 358,549
Less Than 12 Months, Unrealized Losses	(293)	(959)
12 Months or Greater, Estimated Fair Value	5,074	5,521
12 Months or Greater, Unrealized Losses	(5)	(22)
Total Estimated Fair Value	177,986	364,070
Total Unrealized Losses	(298)	(981)
Certificates of deposit
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Estimated Fair Value		5,517
Less Than 12 Months, Unrealized Losses		(3)
12 Months or Greater, Estimated Fair Value		0
12 Months or Greater, Unrealized Losses		0
Total Estimated Fair Value		5,517
Total Unrealized Losses		(3)
Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Estimated Fair Value		16,959
Less Than 12 Months, Unrealized Losses		(11)
12 Months or Greater, Estimated Fair Value		0
12 Months or Greater, Unrealized Losses		0
Total Estimated Fair Value		16,959
Total Unrealized Losses		(11)
Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Estimated Fair Value	138,427	310,160
Less Than 12 Months, Unrealized Losses	(270)	(880)
12 Months or Greater, Estimated Fair Value	5,074	5,521
12 Months or Greater, Unrealized Losses	(5)	(22)
Total Estimated Fair Value	143,501	315,681
Total Unrealized Losses	(275)	(902)
Securities of government sponsored entities
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Estimated Fair Value	34,485	25,913
Less Than 12 Months, Unrealized Losses	(23)	(65)
12 Months or Greater, Estimated Fair Value	0	0
12 Months or Greater, Unrealized Losses	0	0
Total Estimated Fair Value	34,485	25,913
Total Unrealized Losses	$ (23)	$ (65)

Assets Measured at Fair Value o

Assets Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	$ 315.7	$ 387.5
Investments Including Cash Equivalents And Restricted Cash
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	436	466.5
Cash and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	120.3	79
Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	381.8	379.3
Short-term investments | Cash and money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	105.4	69.5
Short-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	7.2	9.1
Short-term investments | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	12	24
Short-term investments | Securities of government-sponsored entities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	21.9	17.7
Short-term investments | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	235.3	259
Long-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	5	5.7
Long-term investments | Securities of government-sponsored entities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	22.5	12.5
Long-term investments | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	26.7	69
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	7.5	10.1
Quoted Prices in Active Markets for Identical Assets (Level 1) | Investments Including Cash Equivalents And Restricted Cash
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	117.6	84.3
Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	110.1	74.2
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	112.6	78.6
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments | Cash and money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	105.4	69.5
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	7.2	9.1
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments | Securities of government-sponsored entities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	5	5.7
Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term investments | Securities of government-sponsored entities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term investments | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	308.2	377.4
Significant Other Observable Inputs (Level 2) | Investments Including Cash Equivalents And Restricted Cash
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	318.4	382.2
Significant Other Observable Inputs (Level 2) | Cash and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	10.2	4.8
Significant Other Observable Inputs (Level 2) | Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	269.2	300.7
Significant Other Observable Inputs (Level 2) | Short-term investments | Cash and money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Other Observable Inputs (Level 2) | Short-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Other Observable Inputs (Level 2) | Short-term investments | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	12	24
Significant Other Observable Inputs (Level 2) | Short-term investments | Securities of government-sponsored entities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	21.9	17.7
Significant Other Observable Inputs (Level 2) | Short-term investments | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	235.3	259
Significant Other Observable Inputs (Level 2) | Long-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Other Observable Inputs (Level 2) | Long-term investments | Securities of government-sponsored entities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	22.5	12.5
Significant Other Observable Inputs (Level 2) | Long-term investments | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	26.7	69
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Investments Including Cash Equivalents And Restricted Cash
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Cash and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Short-term investments | Cash and money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Short-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Short-term investments | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Short-term investments | Securities of government-sponsored entities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Short-term investments | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Long-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Long-term investments | Securities of government-sponsored entities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Long-term investments | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	$ 0	$ 0

Compensation Expense Related to

Compensation Expense Related to Share-Based Compensation (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 6.9	$ 3.6
General and Administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	4.1	1.7
Research and Development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 2.8	$ 1.9

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option exercised	26,000	700,000
Cash received from stock option exercises	$ 0.1	$ 2.8
Common stock issued pursuant to the vesting of restricted stock units (RSUs)	300,000	200,000
Stock options granted	700,000	700,000
Share-based compensation expense	$ 6.9	$ 3.6
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 38.1
Unrecognized compensation cost, weighted average period of recognition	3 years
Stock vesting period	4 years	4 years
Share-based compensation expense	$ 4.4	$ 2.4
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 25
Unrecognized compensation cost, weighted average period of recognition	3 years
Stock vesting period	4 years	4 years
Share-based compensation expense	$ 2.5
Restricted stock units granted	300,000	400,000
Restricted Stock Units (RSUs) | Performance Based Vesting
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 10.1
RSU with performance-based vesting requirements outstanding	400,000
Performance-based RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense		$ 1.2
Performance-based RSUs | Performance Based Vesting
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units granted	230,000	50,000
Performance-based RSUs | Performance Based Vesting | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock vesting period	4 years	4 years
Performance-based RSUs | Performance Based Vesting | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock vesting period	5 years	5 years

Weighted-Average Assumptions fo

Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Detail) - Stock Options	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.40%	1.60%
Expected volatility of common stock	60.00%	66.60%
Dividend yield	0.00%	0.00%
Expected option term	5 years 7 months 6 days	6 years 8 months 12 days

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	1 Months Ended	3 Months Ended
	Feb. 28, 2015	Mar. 31, 2016	Mar. 31, 2015
Class of Stock [Line Items]
Proceeds from common stock issuance	$ 270,700	$ 62	$ 273,525
Common Stock
Class of Stock [Line Items]
Common stock issued	8
Common stock, offering price	$ 36
February Two Thousand Fourteen Shelf Registration [Member]
Class of Stock [Line Items]
Common stock issued		16

Real Estate - Additional Inform

Real Estate - Additional Information (Detail)	1 Months Ended	3 Months Ended
	Dec. 31, 2007USD ($)Building	Mar. 31, 2016USD ($)ft²RenewalOptionsLease_Agreements	Mar. 31, 2015USD ($)	Dec. 31, 2008USD ($)
Real Estate Properties [Line Items]
Sale of facility and associated real property	$ 109,000,000
Mortgage debt retired	47,700,000
Cash received net of transaction costs and debt retirement	$ 61,000,000
Leaseback transaction lease period	12 years
Number of building leased | Building	2
Net deferred gain on real estate sale		$ 13,500,000		$ 39,100,000
Deferred gain recognized on real estate sale		$ 900,000	$ 800,000
Lease expiration year		2,019
Percentage of management fee included in the base annual rent		3.50%
Letter of credit		$ 4,600,000
Lease extension period		10 years
Number of times to renew the lease contract | RenewalOptions		2
Subleased area | ft²		30,000
Rental income from sublease agreement		$ 1,100,000
Reversal of cease use expense		(584,000)	0
Increase in deferred rent		$ (64,000)	$ (27,000)
Sublease
Real Estate Properties [Line Items]
Number of sublease agreements | Lease_Agreements		2
Lease renewal additional periods		1 year
Number of sublease agreement terminated | Lease_Agreements		1
Reversal of cease use expense		$ 800,000
Increase in deferred rent		246,000
Second Sublease
Real Estate Properties [Line Items]
Rental income from sublease agreement		$ 600,000
Lease renewal additional periods		1 year
Lease expiration date		2018-03

Changes to Accrued Cease-Use Li

Changes to Accrued Cease-Use Liability (Detail) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2016	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Beginning balance		$ 1,983	$ 2,678
Change in estimate	[1]	(830)	0
Payments		(110)	(113)
Ending balance		$ 1,043	$ 2,565
[1]	Change in estimate was offset by an increase in deferred rent of approximately $246,000 during the first quarter of 2016.

Loss Per Common Share - Additio

Loss Per Common Share - Additional Information (Detail) - USD ($) $ in Thousands, shares in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Earnings Per Share [Abstract]
Net loss	$ (19,264)	$ (1,192)
Potentially dilutive securities	3.6	3.9
Shares of common stock excluded from computation of diluted earnings per share outstanding	0.5	0.1